ERBB2 and breast cancer: While the prognosis of BC has significantly improved since the introduction of HER2-targeted therapy, the risk of disease recurrence and death remains high in patients with residual invasive disease at surgery, especially when compared to those who achieved pCR through neoadjuvant chemotherapy [28,37,38,39,40].